drugset / Trial / NCT00466219
Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The aim of the study is to assess whether patients with recurrent hepatitis C after liver transplantation will benefit from a treatment with ribavirin/PEG-IFN-alpha combined treatment for 48 weeks.
Timeline
- Start
- 2002-05
- Primary completion
- —
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | — | — |
| Subject | Ribavirin | Small molecule | — | — |